| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2164166 | Update on Cancer Therapeutics | 2008 | 8 Pages |
Abstract
Although testicular germ cell tumors (GCTs) are a model for a curable neoplasm, a significant proportion will relapse and require salvage therapy. While currently available conventional and high-dose chemotherapy salvage regimens attain durable complete remissions in a significant proportion of patients, the long-term outcomes are still suboptimal in this young population. Several novel agents are being evaluated for recurrent germ cell tumors, including chemotherapeutic and biologic agents, notably anti-angiogenic agents. A better understanding of biology may lead to enhanced outcomes for cisplatin-refractory patients with germ cell tumors.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
G. Varuni Kondagunta, Guru Sonpavde, Matthew D. Galsky, Mark T. Fleming, Thomas E. Hutson, Cora N. Sternberg,